Actively Recruiting

Phase 4
Age: 50Years +
All Genders
NCT03059069

The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients

Led by Yonsei University · Updated on 2025-02-24

60

Participants Needed

1

Research Sites

473 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The aim of this study is to investigate the effect of Gliatamin (chonline alphoscerate) on depressive mood in type 2 diabetes patients and demonstrate the impact of improved depressive mood could be influence the patient's quality of life and glycemic control.

CONDITIONS

Official Title

The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients

Who Can Participate

Age: 50Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Type 2 diabetic patients
  • Age 50 years or older
  • Glycemic control: HbA1c 10.0% or lower
  • Beck Depression Inventory (BDI) score between 10 and less than 30
  • Participants able to use contraception if of childbearing potential
  • Understands study procedures and voluntarily agrees to participate with written consent
Not Eligible

You will not qualify if you...

  • Type 1 diabetes, secondary diabetes, or gestational diabetes
  • Current treatment for dementia or depression
  • Uncontrolled psychiatric disorders
  • Beck Depression Inventory (BDI) score 30 or higher
  • Heavy alcohol use
  • Chronic liver diseases such as hemochromatosis, liver cancer, autoimmune liver disease, cirrhosis, or chronic viral hepatitis
  • Allergy or sensitivity to study medication or its components
  • Renal failure, moderate or severe renal impairment, or dialysis
  • Abnormal liver function tests (AST/ALT over three times the upper normal limit)
  • History of alcohol or drug abuse within the past 3 months
  • Premenopausal women who are nursing or pregnant
  • HIV or AIDS infection
  • Chronic pancreatitis or pancreatic cancer

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes Center

Seoul, South Korea, 03722

Actively Recruiting

Loading map...

Research Team

B

Bong-Soo Cha, MD, Ph.D

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients | DecenTrialz